Cross-talk of RNA modification "writers" describes tumor stemness and microenvironment and guides personalized immunotherapy for gastric cancer

被引:0
|
作者
Li, Zhuoqi [1 ,2 ]
Zhang, Xuehong [2 ]
Weng, Wenjie [2 ]
Zhang, Ge [2 ]
Ren, Qianwen [2 ]
Tian, Yuan [1 ,3 ]
机构
[1] Shandong Univ, Shandong Prov Gen Hosp 2, Radiotherapy Dept, Jinan, Peoples R China
[2] Peking Univ, Peking Univ Canc Hosp & Inst, Div Etiol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing, Peoples R China
[3] Shandong Univ, Shandong Prov ENT Hosp, Dept Otolaryngol Head & Neck Surg, Jinan, Peoples R China
来源
AGING-US | 2023年 / 15卷 / 12期
关键词
tumor microenvironment; gastric cancer; RNA modification; WM_Score; immunotherapy; MESSENGER-RNA; BLOCKADE; FEATURES; PACKAGE;
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: RNA modifications, TME, and cancer stemness play significant roles in tumor development and immunotherapy. The study investigated cross-talk and RNA modification roles in the TME, cancer stemness, and immunotherapy of gastric cancer (GC).Methods: We applied an unsupervised clustering method to distinguish RNA modification patterns in GC. GSVA and ssGSEA algorithms were applied. The WM_Score model was constructed for evaluating the RNA modification-related subtypes. Also, we conducted an association analysis between the WM_Score and biological and clinical features in GC and explored the WM_Score model's predictive value in immunotherapy.Results: We identified four RNA modification patterns with diverse survival and TME features. One pattern consistent with the immune-inflamed tumor phenotype showed a better prognosis. Patients in WM_Score high group were related to adverse clinical outcomes, immune suppression, stromal activation, and enhanced cancer stemness, while WM_Score low group showed opposite results. The WM_Score was correlated with genetic, epigenetic alterations, and post-transcriptional modifications in GC. Low WM_Score was related to enhanced efficacy of anti-PD-1/L1 immunotherapy.Conclusions: We revealed the cross-talk of four RNA modification types and their functions in GC, providing a scoring system for GC prognosis and personalized immunotherapy predictions.
引用
收藏
页码:5445 / 5481
页数:37
相关论文
共 36 条
  • [31] Tumor Microenvironment Drives the Cross-Talk Between Co-Stimulatory and Inhibitory Molecules in Tumor-Infiltrating Lymphocytes: Implications for Optimizing Immunotherapy Outcomes
    Franzese, Ornella
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (23)
  • [32] Resveratrol Suppresses Cross-Talk between Colorectal Cancer Cells and Stromal Cells in Multicellular Tumor Microenvironment: A Bridge between In Vitro and In Vivo Tumor Microenvironment Study
    Buhrmann, Constanze
    Shayan, Parviz
    Brockmueller, Aranka
    Shakibaei, Mehdi
    MOLECULES, 2020, 25 (18):
  • [33] Intimate cross-talk between cancer cells and the tumor microenvironment of B-cell lymphomas: The key role of exosomes
    Xu, Biyu
    Wang, Ting
    TUMOR BIOLOGY, 2017, 39 (06)
  • [34] CXCR4 and CXCR7 Signaling Pathways: A Focus on the Cross-Talk Between Cancer Cells and Tumor Microenvironment
    Santagata, Sara
    Ierano, Caterina
    Trotta, Anna Maria
    Capiluongo, Anna
    Auletta, Federica
    Guardascione, Giuseppe
    Scala, Stefania
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [35] Characterizing tumor biology and immune microenvironment in high-grade serous ovarian cancer via single-cell RNA sequencing: insights for targeted and personalized immunotherapy strategies
    Zhao, Fu
    Jiang, Xiaojing
    Li, Yumeng
    Huang, Tianjiao
    Xiahou, Zhikai
    Nie, Wenyang
    Li, Qian
    FRONTIERS IN IMMUNOLOGY, 2025, 15
  • [36] A C-X-C Chemokine Receptor Type 2-Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis
    Zhou, Zhijun
    Xia, Guanggai
    Xiang, Zhen
    Liu, Mingyang
    Wei, Zhewei
    Yan, Jie
    Chen, Wei
    Zhu, Jintao
    Awasthi, Niranjan
    Sun, Xiaotian
    Fung, Kar-Ming
    He, Yulong
    Li, Min
    Zhang, Changhua
    CLINICAL CANCER RESEARCH, 2019, 25 (11) : 3317 - 3328